Acuta Capital Partners, LLC Portfolio Holdings

Acuta Capital Partners, LLC

  • $40.2 Million
  • Q2 2025

Acuta Capital Partners, LLC has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $40.2 Million distributed in 28 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Ocular Therapeutix, Inc with a value of $9.42M, Aadi Bioscience, Inc. with a value of $5.83M, Ascendis Pharma A/S with a value of $3.9M, Insmed Inc with a value of $3.73M, and Argenx Se with a value of $3.69M.

Examining the 13F form we can see an decrease of $12.5M in the current position value, from $52.7M to 40.2M.

Acuta Capital Partners, LLC is based out at Belmont, CA

Below you can find more details about Acuta Capital Partners, LLC portfolio as well as his latest detailed transactions.

Portfolio value $40.2 Million
Healthcare: $40.2 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$961M
$9.42 Million 23.41% of portfolio
1,014,940
Q2 2025 Reduced 16.79%
$35.9M
$5.83 Million 14.49% of portfolio
3,410,402
Q1 2025 Added 84.41%
$10.9B
$3.9 Million 9.68% of portfolio
22,576
Q2 2025 Reduced 3.27%
$16.5B
$3.73 Million 9.27% of portfolio
37,070
Q2 2025 Reduced 65.05%
$35.3B
$3.69 Million 9.18% of portfolio
6,702
Q2 2025 Reduced 4.57%
$7.1B
$2.79 Million 6.93% of portfolio
26,283
Q2 2025 Added 174.5%
$428M
$2.7 Million 6.71% of portfolio
493,735
Q2 2025 Reduced 37.18%
$3.09B
$2.05 Million 5.09% of portfolio
55,693
Q2 2025 Reduced 16.45%
$246M
$1.73 Million 4.3% of portfolio
463,864
Q2 2025 Added 42.49%
$141M
$1.12 Million 2.79% of portfolio
485,669
Q2 2025 New
$2.23B
$1.06 Million 2.62% of portfolio
19,772
Q2 2025 New
$1.55B
$945,000 2.35% of portfolio
75,876
Q2 2025 Reduced 50.56%
$1.97B
$865,000 2.15% of portfolio
23,814
Q2 2025 Added 11.86%
$340M
$410,000 1.02% of portfolio
59,650
Q2 2025 New
Tourmaline Bio Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 33.55%
Unicycive Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Surrozen, Inc.
-
$0 0.0% of portfolio
-
Q1 2025 New
Soleno Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 5.51%
Artiva Biotherapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2025 Added 3.31%
Bright Minds Biosciences Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 18.87%
Cidara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 42.85%
Helix Acquisition Corp Ii
-
$0 0.0% of portfolio
-
Q1 2025 Added 3.49%
-
$0 0.0% of portfolio
-
Q2 2022 New
Oculis Holding Ag
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 14.63%
Praxis Precision Medicines I
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 14.98%
Rapport Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 21.95%
Zymeworks Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 22.2%

Summary

  • Portfolio
  • No. of Stocks 28
  • Current Value $40.2 Million
  • Prior Value $52.7 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 4 stocks
  • Additional Purchases 6 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 13 stocks
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email